CAS Number115550-35-1
SynonymsMarbofloxacino [INN-Spanish]; Marbofloxacin (INN); Marbocyl; Marbofloxacin; MFCD00864820; UNII-8X09WU898T; Zeniquin
Molecular FormulaC17H19FN4O4
Molecular Weight362.36
Purity98%
Density1.6±0.1 g/cm3
Boiling Point570.5±60.0 °C at 760 mmHg
Melting Point268-269ºC
AppearanceYellow or light yellow powder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 115550-35-1 |
| Catalog No. | 2A-9011292 |
| Chinese Name | 马波沙星 |
| Synonyms | Marbofloxacino [INN-Spanish]; Marbofloxacin (INN); Marbocyl; Marbofloxacin; MFCD00864820; UNII-8X09WU898T; Zeniquin |
| Molecular Formula | C17H19FN4O4 |
| Molecular Weight | 362.36 |
| Purity | 98 |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 570.5±60.0 °C at 760 mmHg |
| Melting Point | 268-269ºC |
| Appearance | Yellow or light yellow powder |
| Storage Condition | -20°C Freezer, Under Inert Atmosphere |
| Application | Marbofloxacin is a broad-spectrum antibiotic that inhibits DNA gyrase. |
| HTC | 2934999090 |
| PubChem ID | 329754775 |
| MDL Number | MFCD00864820 |
| SMILES | CN1CCN(CC1)c2c(F)cc3C(=O)C(=CN4N(C)COc2c34)C(O)=O |
| InChI | 1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25) |
| InChI Key | BPFYOAJNDMUVBL-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/11292_1_115550_35_1.pdf |
| Bioactivity | Marbofloxacin is a potent antibiotic of which depends upon its inhibition of DNA-gyrase. Marbofloxacin is a synthetic, broad spectrum bactericidal agent.Target: DNA-gyraseMarbofloxacin is a third-generation fluoroquinolone for veterinary use, the antimicrobial of which depends upon its inhibition of DNA-gyrase and topoisomerase IV. With a broad spectrum bactericidal activity and good efficacy, marbofloxacin is indicated for dermatological, respiratory and urinary tract infections due to both Gram-positive and Gram-negative bacteria and Mycoplasma [1].Administration of Marbofloxacin at 6 mg/kg once daily for 7 days in a Staphylococcus aureus infection in tissue cages in ponies is not effective for the elimination of S. aureus infections from secluded sites [2]. The pharmacokinetic properties of marbofloxacin were investigated in 6 horses after i.v., subcutaneous and oral administration of a single dose of 2 mg/kg bwt and the minimal inhibitory concentrations (MIC) assessed for bacteria isolated from equine infectious pathologies. The clearance of marbofloxacin was mean ± s.d. 0.25 ± 0.05 l/kg/h and the terminal half-life 756 ± 1.99 h. The marbofloxacin absolute bioavailabilities after subcutaneous and oral administration were 98 ± 11% and 62 ± 8%, respectively. Considering the breakpoint values of efficacy indices for fluoroquinolones, a marbofloxacin dosage regimen of 2 mg/kg bwt/24 h by i.v., subcutaneous or oral routes was more appropriate for enterobacteriaceae than for S. aureus [3]. Toxicity: cramps; vomiting; anorexia; soft stools; diarrhoea Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Shen J, et al. Marbofloxacin. Acta Crystallogr Sect E Struct Rep Online. 2012 Apr 1;68(Pt 4):o998-9. [2]. Voermans M, et al. Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. J Vet Pharmacol Ther. 2006 Dec;29(6):555-60. [3]. Bousquet-Melou A, et al. Pharmacokinetics of marbofloxacin in horses. Equine Vet J. 2002 Jul;34(4):366-72. Chemical & Physical Properties Density 1.6±0.1 g/cm3 Boiling Point 570.5±60.0 °C at 760 mmHg Melting Point 268-269ºC Molecular Formula C17H19FN4O4 Molecular Weight 362.356 Flash Point 298.8±32.9 °C Exact Mass 362.139038 PSA 78.25000 LogP -0.55 Vapour Pressure 0.0±1.7 mmHg at 25°C Index of Refraction 1.701 InChIKey BPFYOAJNDMUVBL-UHFFFAOYSA-N SMILES CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2OCN4C)CC1 Storage condition -20°C Freezer, Under Inert Atmosphere |
| Use of | Properties Articles12 Name Marbofloxacin Synonym More Synonyms Marbofloxacin Biological Activity Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Shen J, et al. Marbofloxacin. Acta Crystallogr Sect E Struct Rep Online. 2012 Apr 1;68(Pt 4):o998-9. [2]. Voermans M, et al. Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. J Vet Pharmacol Ther. 2006 Dec;29(6):555-60. [3]. Bousquet-Melou A, et al. Pharmacokinetics of marbofloxacin in horses. Equine Vet J. 2002 Jul;34(4):366-72. Chemical & Physical Properties Molecular Formula C17H19FN4O4 Exact Mass 362.139038 PSA 78.25000 LogP -0.55 Index of Refraction 1.701 InChIKey BPFYOAJNDMUVBL-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Linezolid | 165800-03-3 | 2A-9011192 |
| Lisinopril | 83915-83-7 | 2A-9011203 |
| Lopinavir | 192725-17-0 | 2A-9011228 |
| Losartan | 114798-26-4 | 2A-9011236 |
| Losartan Potassium | 124750-99-8 | 2A-0200254 |
| Mefloquine | 53230-10-7 | 2A-9011319 |
| Meloxicam | 71125-38-7 | 2A-9011329 |
| Melphalan | 148-82-3 | 2A-9011330 |
| Meropenem | 96036-03-2 | 2A-9011349 |
| Meropenem | 119478-56-7 | 2A-9011350 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS